Variables | 2009–2010 Pandemic (n = 16) | 2012–2016 Postpandemic (n = 60) | p value |
---|---|---|---|
Male sex | 8 (50) | 42 (70) | 0.15 |
Age, years | 43 (32–53) | 60 (50–65) | < 0.001 |
BMI | 29.7 (24.0–36.1) | 27.1 (24.5–32.4) | 0.55 |
BMI 30–40 | 6 (37) | 13 (22) | |
BMI > 40 | 2 (12.5) | 6 (10.2) | 0.4 |
Chronic underlying disease | 14 (87.5) | 49 (83) | 0.7 |
Cardiovascular | 1 (6.3) | 24 (40) | 0.015 |
COPD/asthma | 5 (31,3) | 18 (30.0) | >0.9 |
Diabetes | 6 (37.5) | 9 (15.0) | 0.07 |
Malignancy or immuno- suppressive medicationa | 1 (6.3) | 9 (15.0) | 0.7 |
Epilepsy or other neurological disease | 6 (37.5) | 5 (8.3) | 0.009 |
APACHE II score on admission | 14 (10–17) | 17 (13–22) | 0.002 |
SAPS II score on admission | 31 (25–35) | 40 (31–51) | 0.002 |
SOFA score on admission | 5 (3–7) | 6 (3–9) | 0.31 |
SOFA score max | 5 (4–9) | 9 (5–12) | 0.03 |
TISS score | 34 (28–42) | 39 (28–53) | 0.40 |
LOS in ICU, days | 1.9 (1.1–4.8) | 4.3 (2.3–10.7) | 0.31 |
LOS in hospital, days | 8.2 (4.6–10) | 13.0 (6.9–23.3) | 0.009 |
ICU mortality | 0 | 6 (10) | 0.33 |
Hospital mortality | 0 | 10 (16.7) | 0.11 |
6-month mortality | 2 (12.5) | 15 (25) | 0.5 |